BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moukalled NM, Bou-Fakhredin R, Taher AT. Deferasirox: Over a Decade of Experience in Thalassemia. Mediterr J Hematol Infect Dis 2018;10:e2018066. [PMID: 30416698 DOI: 10.4084/MJHID.2018.066] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lai YR, Cappellini MD, Aydinok Y, Porter J, Karakas Z, Viprakasit V, Siritanaratkul N, Kattamis A, Liu R, Izquierdo M, Lasher J, Govindaraju S, Taher A. An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results. Am J Hematol 2022. [PMID: 35560253 DOI: 10.1002/ajh.26592] [Reference Citation Analysis]
2 Barani M, Sargazi S, Hajinezhad MR, Rahdar A, Sabir F, Pardakhty A, Zargari F, Anwer MK, Aboudzadeh MA. Preparation of pH-Responsive Vesicular Deferasirox: Evidence from In Silico, In Vitro, and In Vivo Evaluations. ACS Omega 2021;6:24218-32. [PMID: 34568700 DOI: 10.1021/acsomega.1c03816] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
3 Palagi L, Di Gregorio E, Costanzo D, Stefania R, Cavallotti C, Capozza M, Aime S, Gianolio E. Fe(deferasirox)2: An Iron(III)-Based Magnetic Resonance Imaging T1 Contrast Agent Endowed with Remarkable Molecular and Functional Characteristics. J Am Chem Soc 2021;143:14178-88. [PMID: 34432442 DOI: 10.1021/jacs.1c04963] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
4 Sedgwick AC, Yan KC, Mangel DN, Shang Y, Steinbrueck A, Han HH, Brewster JT 2nd, Hu XL, Snelson DW, Lynch VM, Tian H, He XP, Sessler JL. Deferasirox (ExJade): An FDA-Approved AIEgen Platform with Unique Photophysical Properties. J Am Chem Soc 2021;143:1278-83. [PMID: 33428381 DOI: 10.1021/jacs.0c11641] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 28.0] [Reference Citation Analysis]
5 Matthes J. Antianämika. Arzneiverordnungs-Report 2021 2021. [DOI: 10.1007/978-3-662-63825-5_10] [Reference Citation Analysis]
6 Hsu KF, Wilkins SE, Hopkinson RJ, Sekirnik R, Flashman E, Kawamura A, McCullagh JSO, Walport LJ, Schofield CJ. Hypoxia and hypoxia mimetics differentially modulate histone post-translational modifications. Epigenetics 2021;16:14-27. [PMID: 32609604 DOI: 10.1080/15592294.2020.1786305] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
7 Matthes J. Antianämika. Arzneiverordnungs-Report 2020 2020. [DOI: 10.1007/978-3-662-62168-4_9] [Reference Citation Analysis]
8 Roatsch M, Hoffmann I, Abboud MI, Hancock RL, Tarhonskaya H, Hsu KF, Wilkins SE, Yeh TL, Lippl K, Serrer K, Moneke I, Ahrens TD, Robaa D, Wenzler S, Barthes NPF, Franz H, Sippl W, Lassmann S, Diederichs S, Schleicher E, Schofield CJ, Kawamura A, Schüle R, Jung M. The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases. ACS Chem Biol 2019;14:1737-50. [PMID: 31287655 DOI: 10.1021/acschembio.9b00289] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
9 Matthes J, Mengel K. Antianämika. Arzneiverordnungs-Report 2019 2019. [DOI: 10.1007/978-3-662-59046-1_12] [Reference Citation Analysis]